Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The stimulation of insulin vs. inhibition of glucagon secretion in relation to the antidiabetic action of glucagon-like peptide-1 (GLP-1) is not established. Here, the influence of a 4-wk increase in circulating GLP-1 by inhibition of dipeptidyl peptidase-4 (DPP-4) on 24-h glucose and insulin and glucagon responses to breakfast was studied in subjects with dietary controlled diabetes [age: 65 +/- 8 yr (SD), body mass index: 27.3 +/- 3.3 kg/m(2), fasting plasma glucose: 9.0 +/- 1.3 mmol/liter]. Compared with placebo (n = 19), a specific DPP-4 inhibitor [(1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine) (LAF237); 100 mg daily, n = 18] reduced fasting glucose by 0.70 mmol/liter (P = 0.037), 4-h prandial glucose excursion by 1.45 mmol/liter (P < 0.001), and mean 24-h glucose by 0.93 mmol/liter (P < 0.001). Baseline and postprandial active GLP-1 were increased by LAF237. The glucagon response to breakfast was reduced by LAF237 (glucagon levels at 60 min were 88 +/- 8 pg/ml before treatment vs. 77 +/- 5 pg/ml after; P = 0.001). In contrast, the overall insulin levels were not altered. The 4-wk reduction in glucagon correlated with the reduction in 2-h glucose (r = 0.61; P = 0.008). No such association was observed for insulin. Thus, improved metabolic control by DPP-4 inhibition in type 2 diabetes is seen in association with reduced glucagon levels and, despite the lower glycemia, unaltered insulin levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 3×
“This would be similar to the increase ininsulinsensitivityseenafter6wkofcontinuousscinfusion of GLP-1 ( 6 ).”
InfluentialDipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 4×
“A difference exists between these peptides, however , because GLP-1 inhibits glucagon secretion (1–3), whereas both GIP (29) and PACAP (27) stimulate glucagon secretion in humans.”
InfluentialGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 6×
“Three approaches are possible: the continuous iv or sc infusion of GLP-1 (5, 6), the use of DPP-4-resistant GLP-1 analogs (3), or the use of compounds that inhibit the activity of DPP-4 (17).”
InfluentialStudies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“To develop the antidiabetogenic action of GLP-1 is difficult due to its rapid inactivation by the enzyme dipeptidyl peptidase-4 (DPP-4) (15, 16).”
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Biological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Winzell, M. S., & Ahrén, B. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s215 · Cited by 1,026
Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S.-H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01461 · Cited by 775
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
“With chronic use of DPP4 inhibitors and lower blood glucose levels, changes in plasma glucagon can appear to be greater than those of insulin (6).”
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes
Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C.-C., Edmondson, S., Feeney, W. P., He, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2988 · Cited by 491
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Self-citationBosi, E., Camisasca, R. P., Collober, C., Rochotte, E., & Garber, A. J. (2007) · Diabetes Care · doi:10.2337/dc06-1732 · Cited by 447
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“7 mmol/l (0–30 mg/dl) above target [42] 1.”
BackgroundInfluentialPhysiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
BARNETT, A. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01178.x · Cited by 391
Chu, Z.-L., Carroll, C., Alfonso, J., Gutierrez, V., He, H., Lucman, A., Pedraza, M., Mondala, H., Gao, H., Bagnol, D., et al. (2008) · Endocrinology · doi:10.1210/en.2007-0966 · Cited by 387
Identifying emerging topics in science and technology
Small, H., Boyack, K. W., & Klavans, R. (2014) · Research Policy · doi:10.1016/j.respol.2014.02.005 · Cited by 378
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
Fonseca, V., Schweizer, A., Albrecht, D., Baron, M. A., Chang, I., & Dejager, S. (2007) · Diabetologia · doi:10.1007/s00125-007-0633-0 · Cited by 369
Self-citationMari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Self-citationDipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
GORRELL, M. D. (2005) · Clinical Science · doi:10.1042/cs20040302 · Cited by 334
Highly Efficient Asymmetric Synthesis of Sitagliptin
Hansen, K. B., Hsiao, Y., Xu, F., Rivera, N., Clausen, A., Kubryk, M., Krska, S., Rosner, T., Simmons, B., Balsells, J., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902462q · Cited by 314
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
Pi-Sunyer, F. X., Schweizer, A., Mills, D., & Dejager, S. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.12.009 · Cited by 312
Self-citationAhrén, B., Pacini, G., Foley, J. E., & Schweizer, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1936 · Cited by 309
Self-citationFerrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahrén, B., Byiers, S., Shao, Q., & Dejager, S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00994.x · Cited by 297
Self-citationTherapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288
Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271
Self-citationComparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270
Self-citationGarber, A. J., Schweizer, A., Baron, M. A., Rochotte, E., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00684.x · Cited by 268
Self-citationBergman, A. J., Stevens, C., Zhou, Y., Yi, B., Laethem, M., De Smet, M., Snyder, K., Hilliard, D., Tanaka, W., Zeng, W., et al. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.015 · Cited by 265
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
The role of dysregulated glucagon secretion in type 2 diabetes
D'Alessio, D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01449.x · Cited by 238
“Because changes in plasma glucagon have frequently been more pronounced than changes in insulin during chronic use of DPP-4 inhibitors [67], there has been some tendency to attribute the predominant pharmacologic effect of these compounds to inhibition of α-cells.”
BackgroundGlucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
Holst, J. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0107-1 · Cited by 228
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Understanding bile acid signaling in diabetes: From pathophysiology to therapeutic targets
Ferrell, J. M., & Chiang, J. Y. L. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0043 · Cited by 139
Dipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
“and suppressed glucagon secretion with a decrease in HbA1c [78].”
Steven, S., Hausding, M., Kröller-Schön, S., Mader, M., Mikhed, Y., Stamm, P., Zinßius, E., Pfeffer, A., Welschof, P., Agdauletova, S., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0465-x · Cited by 114
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Eleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
“Hepatic glucose production is also decreased by vildagliptin, resulting in lower fasting glucose levels [104-106].”
BackgroundBray, G. M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050459 · Cited by 52
Byrd, J. B., Shreevatsa, A., Putlur, P., Foretia, D., McAlexander, L., Sinha, T., Does, M. D., & Brown, N. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.012 · Cited by 52
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Christensen, A. S., Hædersdal, S., Støy, J., Storgaard, H., Kampmann, U., Forman, J. L., Seghieri, M., Holst, J. J., Hansen, T., Knop, F. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0408 · Cited by 48
Nauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12802 · Cited by 44
“quential improvements in glucose control can only partially be inhibited by the GLP-1 receptor agonist exendin [9-39].”
BackgroundMethodInfluentialHuang, J.-H., Chen, Y.-C., Lee, T.-I., Kao, Y.-H., Chazo, T.-F., Chen, S.-A., & Chen, Y.-J. (2016) · Peptides · doi:10.1016/j.peptides.2016.02.007 · Cited by 36
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia
Suppli, M. P., Lund, A., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2015.10.029 · Cited by 35
Management of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
Metadata
- Authors
- Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-05
- Volume
- 89
- Issue
- 5
- Pages
- 2078-2084
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2036167841
- Cited by
- 710
- References
- 28
- FWCI
- 40.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.